CDX2、β-连环蛋白和WNT免疫标志物对评估结肠癌患者疾病进展或死亡风险有用吗？
ARE CDX2, BETA-CATENIN AND WNT IMMUNOMARCHERS USEFUL FOR EVALUATING THE CHANCE OF DISEASE PROGRESSION OR EVOLUTION TO DEATH IN PATIENTS WITH COLORECTAL CANCER?
作者信息
Bremer Fabiola Pabst, Czeczko Nicolau Gregori, CollaÇo Luiz Martins, Rutz Letícia Elizabeth Augustin Czeczko, Gionedis Guilherme, Yamakawa Camila Kienen
机构信息
Mackenzie Evangelical Faculty of Paraná, Curitiba, PR, Brazil.
University Evangelical Mackenzie Hospital, Curitiba, PR, Brazil.
出版信息
Arq Bras Cir Dig. 2020 Dec 18;33(3):e1534. doi: 10.1590/0102-672020200003e1534. eCollection 2020.
BACKGROUND
Colorectal cancer (CRC) is one of the most common types of cancer in the world. Over time, intestinal epithelial cells undergo mutations that may lead to proliferative advantage and the emergence of cancer. Mutations in the beta-catenin pathway are amongst those described in the development of CRC.
AIM
To verify the existence of a relation between the presence of Wnt3, beta-catenin and CDX2 in colorectal cancer samples and clinical outcomes such as disease progression or death.
METHOD
Wnt3a, beta-catenin and CDX2 immunohistochemistry was performed on CRC tissue microarray samples (n=122), and analysis regarding the relation between biomarker expression and disease progression or death was performed.
RESULTS
No significant difference was found between the presence or absence of CDX2, beta-catenin or Wnt3a expression and clinical stage, tumor grade, disease progression or death.
CONCLUSION
CDX2, beta-catenin and Wnt3a are not useful to predict prognosis in patients with CRC.
背景
结直肠癌（CRC）是世界上最常见的癌症类型之一。随着时间的推移，肠上皮细胞会发生突变，这可能导致增殖优势和癌症的出现。β-连环蛋白信号通路的突变是在结直肠癌发生过程中被描述的突变之一。
目的
验证结直肠癌样本中Wnt3、β-连环蛋白和CDX2的存在与疾病进展或死亡等临床结局之间是否存在关联。
方法
对结直肠癌组织微阵列样本（n = 122）进行Wnt3a、β-连环蛋白和CDX2免疫组织化学检测，并分析生物标志物表达与疾病进展或死亡之间的关系。
结果
CDX2、β-连环蛋白或Wnt3a表达的有无与临床分期、肿瘤分级、疾病进展或死亡之间未发现显著差异。
结论
CDX2、β-连环蛋白和Wnt3a对预测结直肠癌患者的预后无用。
Zotero 插件